Physician profile
Vicky Marsh
NPI 1861748717
$2,670.69
in general payments reported to CMS, 2019-2025
29 companies · $432 in 2025
The $432 reported for 2025 was more than what 76% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $174 · 2021: $1,179 · 2023: $100 · 2024: $527 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,058.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $446.57 | 2021 | |
| Gilead Sciences, INC. | $334.98 | 2020-2025 | |
| Janssen Biotech, INC. | $243.03 | 2021 | |
| Novo Nordisk INC | $171.89 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $158.75 | 2023-2025 | Invega Sustenna |
| Indivior INC. | $153.37 | 2019-2025 | Sublocade |
| Alkermes, INC. | $148.67 | 2023-2025 | Aristada, Vivitrol, Lybalvi |
| Janssen Products, LP | $128.99 | 2021 | |
| Neurocrine Biosciences, INC. | $117.64 | 2024 | Ingrezza |
| Merck Sharp & Dohme LLC | $90.63 | 2019 | |
| Abbvie INC. | $75.18 | 2019-2021 | |
| Braeburn INC. | $73.32 | 2024-2025 | Brixadi |
| Otsuka America Pharmaceutical, INC. | $58.04 | 2024-2025 | Rexulti |
| Almatica Pharma LLC | $49.33 | 2024-2025 | Loreev Xr |
| Lundbeck LLC | $48.33 | 2024-2025 | Rexulti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $47.12 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $45.40 | 2024-2025 | Cologuard Collection Kit |
| Ironshore Pharmaceuticals INC. | $42.33 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.70 | 2023-2024 | Caplyta |
| Hologic Sales and Service, LLC | $25.19 | 2024 | Aptima, Thinprep 2000 Processor |
| E.R. Squibb & Sons, L.L.C. | $24.95 | 2025 | Cobenfy |
| Orexo US, INC. | $22.59 | 2021 | |
| Collegium Pharmaceutical, INC. | $21.60 | 2025 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $21.56 | 2020 | |
| Emd Serono, INC. | $19.05 | 2021 | |
| Phadia US INC. | $17.27 | 2023 | Immunocap |
| Lilly USA, LLC | $15.79 | 2024 | Zepbound, Mounjaro |
| Amgen INC. | $14.94 | 2020 | |
| Vivus LLC | $13.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicky Marsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.